01/07/2022 Sitagliptin for treating type 2 diabetes mellitus
The Ministry of Health’s Drug Advisory Committee has recommended:
- sitagliptin 25 mg, 50 mg and 100 mg tablets
in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.
Subsidy status
RSitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
NRSDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.